$OBIO Cashflow Statement | Understand Stock

$OBIO

$5.78 +$0.23 (4.14%) Close

$OBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Interest income from investments held in Trust Account
Depreciation and amortization
Shares issued as compensation for consulting services
Stock-based compensation
Acquired in-process research and development
Loss on fair value adjustment of warrant liability
Loss on fair value of strategic investments
Non-cash interest expense on liability related to the royalty purchase agreement
Accretion and interest related to marketable securities
Loss on debt extinguishment
Non-cash lease expense
Change in the fair value of derivative liability
Amortization of deferred financing fees
Other

Changes in operating assets and liabilities:
Prepaid expenses
Accounts payable
Accrued expenses
Accrued expenses - related party
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable, accrued expenses and other liabilities
Operating lease liabilities - current and non-current
Deferred revenue
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash withdrawn from Trust Account to redeem Public Shares
Purchases of property and equipment
Sales of marketable securities
Purchases of marketable securities
Purchases of strategic investments
Asset acquisition, net of cash acquired
Net cash (used in) provided by investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Redemption of Public Shares
Repayment of debt financing, inclusive of debt extinguishment costs
Proceeds from sale of common stock and pre-funded warrants, net of issuance costs
Proceeds from the royalty purchase agreement
Proceeds from issuance of Series A preferred stock
Repayment of royalty liability
Proceeds from Hercules term loan
Proceeds from At-The-Market offering, net of issuance costs
Proceeds from exercise of warrants
Warrant repurchases
Proceeds from exercise of stock options
Effect of merger, net of transaction costs (Note 3)
Proceeds from private placement financing
Restricted stock units withheld for tax
Deferred financing costs
Net cash provided by financing activities

Net change in cash
Net increase (decrease) in cash and cash equivalents
Cash - beginning of the period
Cash - end of the period
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
Cash paid during the year ended December 31:
Interest
Supplemental disclosure of noncash activities
Deferred offering and merger costs in accounts payable and accrued expenses
Warrants issued pursuant to private placement financing
Operating lease right-of-use asset obtained in exchange for new operating lease liabilities
Increase in accounts payable, accrued expenses and other liabilities related to fixed assets
Common stock issued pursuant to asset acquisition
Warrants issued pursuant to debt financing
Warrants issued pursuant to the royalty purchase agreement

Comments